Physician profile
Alexandr V Arakelov
NPI 1861481665
$1,700.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $38.03 · 2021: $293 · 2022: $841.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $276.00 | 2019-2022 | |
| Amgen INC. | $214.14 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $196.41 | 2019 | |
| Mallinckrodt Hospital Products INC. | $189.00 | 2021-2022 | |
| Medtronic, INC. | $181.91 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.98 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.36 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $77.66 | 2019-2022 | |
| Vifor Pharma, INC. | $63.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $62.17 | 2019 | |
| Opko Pharmaceuticals, LLC | $43.73 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $41.01 | 2022 | |
| Glaxosmithkline, LLC. | $35.58 | 2021-2022 | |
| Horizon Therapeutics Plc | $32.35 | 2022 | |
| Daiichi Sankyo INC. | $22.96 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $18.59 | 2022 | |
| Boston Scientific Corporation | $18.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.03 | 2019 | |
| Genzyme Corporation | $12.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandr Arakelov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.